A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma
- Satwani, P.
- Ahn, K. W.
- Carreras, J.
- Abdel-Azim, H.
- Cairo, M. S.
- Cashen, A.
- Chen, A. I.
- Cohen, J. B.
- Costa, L. J.
- Dandoy, C.
- Fenske, T. S.
- Freytes, C. O.
- Ganguly, S.
- Gale, R. P.
- Ghosh, N.
- Hertzberg, M. S.
- Hayashi, R. J.
- Kamble, R. T.
- Kanate, A. S.
- Keating, A.
- Kharfan-Dabaja, M. A.
- Lazarus, H. M.
- Marks, D. I.
- Nishihori, T.
- Olsson, R. F.
- Prestidge, T. D.
- Rolon, J. M.
- Savani, B. N.
- Vose, J. M.
- Wood, W. A.
- Inwards, D. J.
- Bachanova, V.
- Smith, S. M.
- Maloney, D. G.
- Sureda, A.
- Hamadani, M.
DOIAbstract
Autologous hematopoietic cell transplantation (AutoHCT) is a potentially curative treatment modality for relapsed/refractory Hodgkin lymphoma (HL). However, no large studies have evaluated pre-transplant factors predictive of outcomes of AutoHCT in children, adolescents and young adults (CAYA, age <30 years). In a retrospective study, we analyzed 606 CAYA patients (median age 23 years) with relapsed/refractory HL who underwent AutoHCT between 1995–2010. The probabilities of progression free survival (PFS) at 1, 5 and 10 years were 66% (95% CI: 62–70), 52% (95% CI: 48–57) and 47% (95% CI: 42–51), respectively. Multivariate analysis for PFS demonstrated that at the time of AutoHCT patients with Karnofsky/Lansky score ≥90, no extranodal involv...
Add to ORKG